A clinical update_in_hypertension

A Clinical Updatein Hypertension

See Important Safety Information, including boxed warning for pregnancy, on slides 25-27

TAK-OEC

EDARBI is a trademark of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.Trademarks are the property of their respective owners.

TAK-OEC

Hypertension Affects Over 50% of Americans Over Age 55

74.5 million US adults (1 in 3) are hypertensive1

Lifetime risk (over next 25 years) of hypertension in non-hypertensive adults aged ≥55 years is 90%2,3

Percent of Population

Prevalence of Hypertension in Adults ≥20 Years of Age (by age and sex)

70 90806050403020100

20-34

35-44

45-54

55-64

65-74

75+

Men

Women

127

2416

3938

5354

6571

6577

Ag

e (y

ears

)

1. Adapted from Lloyd-Jones D, et al. Circulation. 2010;121:e46-e215. 2. Chobanian AV, et al. Hypertension. 2003;42:1206-1252. 3. Vasan RS, et al. JAMA. 2002;287:1003-1010.

1. Adapted from Lloyd-Jones D, et al. Circulation. 2010;121:e46-e215. 2. Chobanian AV, et al. Hypertension. 2003;42:1206-1252. 3. Vasan RS, et al. JAMA. 2002;287:1003-1010.


2

TAK-OEC

37 Million Patients Do Not Have Their Blood Pressure Under Control1

Up to 54% of patients with hypertension are uncontrolled1,2

More than two-thirds of hypertensive individuals will require 2 or more antihypertensive drugs to achieve effective blood pressure control3

1. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011;60:103-108. 2. Egan B, et al. JAMA. 2010;303:2043-2050. 3. Chobanian AV, et al. Hypertension. 2003;42:1206-1252.

1. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2011;60:103-108. 2. Egan B, et al. JAMA. 2010;303:2043-2050. 3. Chobanian AV, et al. Hypertension. 2003;42:1206-1252. 3

Per

cen

tag

e o

f C

on

tro

lled

H

yper

ten

sive

Pat

ien

tsHypertension Control Rates


TAK-OEC

Hypertension and Cardiovascular Outcomes

Epidemiological studies have shown that elevations in BP are associated with an increased risk of CV events

Absolute risk increases progressively with increasing BP

Lowering blood pressure reduces the risk of fatal and nonfatal CV events, primarily strokes and myocardial infarctions

Control of high BP should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise and limited sodium intake

There are no controlled trials demonstrating risk reduction with EDARBI

4 EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011.


TAK-OEC

Risk of CV Death is Estimated to Double With Each 20/10 mm Hg Increase in BP*

Adapted from 1. Chobanian AV, et al. JAMA. 2003;289:2560-2572. 2. Lewington S, et al. Lancet. 2002;360:1903-1913.Adapted from 1. Chobanian AV, et al. JAMA. 2003;289:2560-2572. 2. Lewington S, et al. Lancet. 2002;360:1903-1913.

8

6

4

2

0115/75 135/85 155/95 175/105

2X

4X

8X

SBP/DBP (mm Hg)

Flo

atin

g A

bso

lute

R

isk

of

CV

Mo

rtal

ity

Study Design: A meta-analysis of 1 million adults from 61 prospective observational studies of blood pressure and mortality was performed.2 Total observational period included 12.7 million person-years. Patients had no previous vascular disease recorded at baseline. Outcomes included 56,000 vascular deaths and 66,000 other deaths at ages 40 to 89 years.2


5

*Individuals aged 40-69 years, starting at BP 115/75 mm Hg.

TAK-OEC

Reducing SBP Lowers Risk of CV Events and Stroke

6

Relative risk estimates of coronary heart disease (CHD) events* and strokein the blood pressure difference trials and in epidemiological cohort studies†

*Defined as fatal or non-fatal myocardial infarction or sudden cardiac death but excluding “silent” infarcts† BP reduction of 10 mm Hg systolic or 5 mm Hg diastolic, in the age group 60-69 yearsNR=not reported

No. of Trials

No. of Events

Relative Risk(95% CI)

Blood Pressure Difference Trials HRCHD events 71 9811 0.78

Stroke 45 5420 0.59

Cohort Studies

CHD events 61 10 450 0.75

Stroke 61 2939 0.64

0.5 0.7 1 1.4 2Treatment better

Placebobetter

See Important Safety Information, including boxed warning for pregnancy, on slides 25-27Adapted from: Law MR, Morris JK, and Wald NJ. Brit Med J. 2009;338:b1665 doi: 10.1136/bmj.b1665

TAK-OEC

Modest* Improvements in SBP Reduction May Lower CV Risk

Reduction in BP

After Intervention

Before Intervention

% Reduction in Mortality†

Reduction in SBP(mm Hg)

StrokeCoronary

Heart Disease2 -6 -43 -8 -55 -14 -9

1. Adapted from Chobanian AV, et al. Hypertension. 2003;42:1206-1252. 2. Stamler R. Hypertension. 1991;17(supp 1):I-16-I-20.

Study Design: SBP and mortality was analyzed in 5 large population follow-up studies, the Multiple Risk Factor Intervention Trial, the Whitehall Civil Servants study, the Western Electric study, the Framingham Heart study, and the Chicago Heart Association Detection Project in Industry. Follow-up lasted from 6 to 19 years and The multivariate coefficients for the 5 studies were similar and averaged.2


*Modest is defined as a decrease in SBP of 2-5 mm Hg.†Population estimation.

TAK-OEC

EDARBI Profile

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011.1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011.

EDARBI is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension in adults to lower blood pressure

Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions

It may be used alone or in combination with other antihypertensive agents

K+

H3C

O

O CH3

-

WARNING: AVOID USE IN PREGNANCY

When pregnancy is detected, discontinue EDARBI as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS AND PRECAUTIONS in

complete Prescribing Information.

8

Please see Important Safety Information, including boxed warning, on slides 25-27

TAK-OEC

EDARBI Key Points

EDARBI 80 mg was statistically superior to Diovan® 320 mg and Benicar® 40 mg in reducing 24-hour mean ambulatory and clinic systolic blood pressure (SBP) in head-to-head studies

EDARBI 80 mg sustained significant SBP reductions across the 24-hour dosing interval

Treatment with EDARBI was well tolerated, and the most common adverse reaction occurring more frequently with EDARBI than placebo in adults was diarrhea (2% vs. 0.5%)

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File.Trademarks are the property of their respective owners.

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File.Trademarks are the property of their respective owners. 9


TAK-OEC

EDARBI Key Points (cont.)

Additional reduction in 24-hour mean ambulatory SBP with EDARBI 80 mg when co-administered with:

– Chlorthalidone (CLD) 25 mg compared with CLD 25 mg alone

– Amlodipine (AML) 5 mg compared with AML 5 mg alone

Small reversible increases in serum creatinine are seen in patients receiving 80 mg of EDARBI. The increase may be larger when co-administered with chlorthalidone or hydrochlorothiazide and was more likely in patients who had moderate to severe renal impairment at baseline or >75 years of age

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 10


TAK-OEC

EDARBI Dosage and Administration

The recommended dose in adults is 80 mg taken orally once daily. Consider a starting dose of 40 mg for patients who are treated with high doses of diuretics

Volume and/or salt depletion should be corrected prior to administering EDARBI

May be taken with or without food EDARBI may be administered with other antihypertensive agents No dose adjustment is necessary in elderly patients, patients with miId-to-

severe renal impairment, end-stage renal disease, or mild-to-moderate hepatic dysfunction

Patients taking EDARBI who had moderate to severe renal impairment or who were >75 years of age were more likely to report serum creatinine increases

Has not been studied in patients with severe hepatic impairment

Recommended Dose 80 mg once daily



summary of phase 3 clinical trials: efficacy

TAK-OEC


TAK-OEC

Extensively Studied in 3672 Patients Taking EDARBI

StudyLength (weeks)

Total Studied*

1 EDARBI vs placebo, Diovan, Benicar 6 1291

2 EDARBI vs placebo, Benicar 6 1275

3 EDARBI vs Diovan 24 984

4 EDARBI vs ramipril 24 879

5 EDARBI vs placebo in black subjects 6 410

6 EDARBI + CLD vs CLD alone 6 551

7 EDARBI + AML vs AML alone 6 566

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File; 3. White WB, et al. Hypertension. 2011;57:413-420; 4. Bakris GL, et al. J Clin Hypertens. 2011;13:81-88.

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File; 3. White WB, et al. Hypertension. 2011;57:413-420; 4. Bakris GL, et al. J Clin Hypertens. 2011;13:81-88. 13


TAK-OEC

Randomization

N=1291

Forced Titration

Study 1 Design: EDARBI vs Placebo, Diovan, Benicar

EDARBI20 mg QDEDARBI

20 mg QD

Placebo QDPlacebo QD

Benicar20 mg QDBenicar

20 mg QD

ScreeningScreening

1 week 2 weeks 2 weeks 4 weeks

ABPM


40 mg QD


80 mg QD

Placebo QDPlacebo QD

Diovan320 mg QD

Diovan320 mg QD

Benicar40 mg QDBenicar

40 mg QD

ABPM

1. Data on File. 1. Data on File.


40 mg QD

Diovan160 mg QD

Diovan160 mg QD

Single-blind placebo

run-in phase

Single-blind placebo

run-in phase

14

Primary endpoint: 24-hour mean

ambulatory SBP


TAK-OEC

Study 1: Reductions in 24-Hour Mean Ambulatory SBP at Week 6

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File; 3. White WB, et al. Hypertension. 2011;57:413-420.

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File; 3. White WB, et al. Hypertension. 2011;57:413-420.

Mean baseline 24-hour mean ambulatory SBP: 144.9 mm Hg

▼Clinic SBP differences between EDARBI and active comparators were consistent with mean ambulatory results

▼Similar results were observed in Study 2 and Study 3

▼Placebo lowered 24-hour mean ambulatory SBP by 0.25 mm Hg. Data shown are placebo-corrected.

P<0.001 vs Diovan 320 mgP=0.009 vs Benicar 40 mg

Diovan 320 mg

Benicar 40 mg

EDARBI 80 mg

-14.3 mm Hg

-11.7 mm Hg

-10.0mm Hg

EDARBI 80 mg Is Statistically Superior to Diovan 320 mg and Benicar 40 mg in Reducing 24-Hour Mean Ambulatory and Clinic SBP

Ch

ang

e i

n S

BP

, m

m H

g

15

N=1291


TAK-OEC

SB

P, m

m H

g

Sustained Efficacy at Each Hour Over 24 Hours in a 6-Week Study

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011; 2. White WB, et al. Hypertension. 2011;57:413-420.

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011; 2. White WB, et al. Hypertension. 2011;57:413-420.

Study 1: Mean Ambulatory SBP at Each Hour With EDARBI 80 mg at Week 6

Mean baseline 24-hour mean ambulatory SBP: 144.9 mm HgHour Post Dose

Treatment Group:

EDARBI 80 mg (N=285) Benicar 40 mg (N=290)Diovan 320 mg (N=282)Placebo (N=154)

16


TAK-OEC

EDARBI 80 mg Was Statistically Superior in Reducing 24-Hour Mean Ambulatory and Clinic SBP in Multiple Head-to-Head Trials



Reduction in 24-Hour Mean Ambulatory SBP Across 3 Studies

STUDY 1 at Week 6 STUDY 2 at Week 6 STUDY 3 at Week 24

-14.3 mm Hg

P<0.001 vs DiovanP=0.009 vs Benicar P=0.038 P<0.001

-13.2 mm Hg

-11.7 mm Hg

-10.0mm Hg

-15.3 mm Hg

-11.2 mm Hg

-11.3mm Hg

Mean baseline 24-hour mean ambulatory SBP: Study 1=144.9 mm Hg; Study 2=146.2 mm Hg; Study 3=145.6 mm Hg

Diovan 320 mg

Benicar 40 mg

EDARBI 80 mg

▼ Clinic SBP differences between EDARBI and active comparators were consistent with mean ambulatory results

▼ Study 1: Placebo lowered 24-hour mean ambulatory SBP by 0.25 mm Hg. Data shown are placebo-corrected.

▼ Study 2: Placebo lowered 24-hour mean ambulatory SBP by 1.4 mm Hg. Data shown are placebo-corrected.

▼ Study 3: There was no placebo arm in this study.

Ch

ang

e i

n S

BP

, m

m H

g

17

N=1291 N=1275 N=984


TAK-OEC

N=1291 N=984

EDARBI 80 mg Reduced Clinic SBP More than Diovan 320 mg

Reduction in Clinic SBP With EDARBI 80 mg and Diovan 320 mg Across 2 StudiesSTUDY 1 at Week 6 STUDY 3 at Week 24

-9.5mm Hg

-11.6mm Hg

-14.9mm Hg

-16.9mm Hg

Diovan 320 mg

EDARBI 80 mg

Mean baseline clinic SBP: Study 1=157.4 mm Hg; Study 3=157.2 mm Hg

P<0.001

P<0.001

Ch

ang

e i

n S

BP

, m

m H

g

▼Primary endpoint was change in 24-hour mean ambulatory SBP. Placebo lowered clinic SBP by 1.8 mm Hg in Study 1. Data shown for Study 1 are placebo-corrected. There was no placebo arm in Study 3

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File.; 3. White WB, et al. Hypertension. 2011;57:413-420

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File.; 3. White WB, et al. Hypertension. 2011;57:413-420 18


TAK-OEC

EDARBI 80 mg Reduced Clinic SBP More than Benicar 40 mg

STUDY 1 at Week 6 STUDY 2 at Week 6

-11.4mm Hg -12.8

mm Hg-14.9

mm Hg -15.5mm Hg

Benicar 40 mg

EDARBI 80 mg

Mean baseline clinic SBP: Study 1=157.4 mm Hg; Study 2=159.0 mm Hg

Reduction in Clinic SBP With EDARBI 80 mg and Benicar 40 mg Across 2 Studies

P=0.008 P=0.043

▼Primary endpoint was change in 24-hour mean ambulatory SBP. Placebo lowered clinic SBP by 1.8 mm Hg in Study 1 and by 2.1 mm Hg in Study 2. Data shown are placebo-corrected



Ch

ang

e i

n S

BP

, m

m H

g

19

N=1291 N=1275


TAK-OEC

EDARBI Responder Rates

Percent Reaching Target ResponsePercent Reaching Target Response

49% 58%STUDY 1At Week 6

P=0.05

STUDY 3At Week 24

P=0.002

STUDY 1At Week 6

P=0.05

STUDY 2At Week 6P=0.402

47% 59%

49% 58%

53% 57%

Diovan 320 mg

Benicar 40 mg

EDARBI 80 mg

1. White WB, et al. Hypertension. 2011;57:413-420; 2. Bakris GL, et al. J Clin Hypertens. 2011;13:81-88; 3. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 4. Data on File.

1. White WB, et al. Hypertension. 2011;57:413-420; 2. Bakris GL, et al. J Clin Hypertens. 2011;13:81-88; 3. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 4. Data on File.

Responder Rates With EDARBI 80 mg Across 3 Studies

Mean baseline clinic SBP: Study 1=157.4 mm Hg; Study 2=159.0 mm Hg; Study 3=157.2 mm Hg

20

Response to therapy defined as achieving a reduction in clinic SBP ≥20 mm Hg and/or reaching a clinic SBP of <140 mm Hg.


TAK-OEC

Effective When Administered With a Diuretic

Study 6: EDARBI 80 mg + CLD 25 mg Reduction in 24-Hour Mean Ambulatory SBP at Week 6

CLD 25 mg

-15.9mm Hg

Mean baseline ambulatory 24-hour SBP: 152.2 mm Hg

P<0.001

Ch

ang

e i

n S

BP

, m

m H

g

EDARBI 80 mg + CLD 25 mg

-31.3mm Hg

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File. 1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File.

▼Clinic SBP differences between EDARBI 80 mg + CLD 25 mg and placebo + CLD 25 mg were consistent with mean ambulatory results

▼The recommended dose in adults is 80 mg taken orally once daily. Consider a starting dose of 40 mg for patients who are treated with high doses of diuretics.

21

EDARBI has about its usual blood pressure lowering

effect size when added to a thiazide-type diuretic (CLD)

N=551


TAK-OEC

Effective When Administered With a Calcium Channel Blocker

Study 7: EDARBI 80 mg + AML 5 mg Reduction in 24-Hour Mean Ambulatory SBP at Week 6

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File. 1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File.

-13.6mm Hg

AML 5 mg

-24.5mm Hg

EDARBI 80 mg + AML 5 mg

Mean baseline ambulatory 24-hour SBP: 153.4 mm Hg

▼Clinic SBP differences between EDARBI 80 mg + AML 5 mg and placebo + AML 5 mg were consistent with mean ambulatory results

P<0.001

Ch

ang

e i

n S

BP

, m

m H

g

22

EDARBI has about its usual blood pressure lowering

effect size when added to a calcium channel blocker

(AML)

N=566


TAK-OEC

Safety Endpoints

A total of 4814 patients were evaluated for safety with 20 mg*, 40 mg, and 80 mg of EDARBI– 1704 patients treated ≥6 months

– 588 treated ≥1 year

Rates of withdrawals due to adverse events were similar for patients treated with placebo and EDARBI

Placebo(N=801)

EDARBI 40 mg (N=1072)

EDARBI 80 mg (N=1074)

2.4% 2.2% 2.7%

Rate of Withdrawals Due to Adverse Events


*EDARBI 20 mg is not an approved dose


TAK-OEC

Indication and Usage

EDARBI is an angiotensin II receptor blocker indicated for the treatment of hypertension in adults to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. There are no controlled trials demonstrating risk reduction with EDARBI, but at least one pharmacologically similar drug has demonstrated such benefits.

Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. EDARBI may be used either alone or in combination with other antihypertensive agents.

24


TAK-OEC

Important Safety Information

Avoid Fetal or Neonatal Exposure: Drugs that act directly on the renin‐angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women during the second and third trimester. Nursing mothers should discontinue either nursing or EDARBI.

Correct volume or salt depletion prior to administration of EDARBI: In patients with an activated renin‐angiotensin system, such as volume‐ and/or salt‐depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with EDARBI.

Please see Takeda representative for complete Prescribing Information.

WARNING: AVOID USE IN PREGNANCY

When pregnancy is detected, discontinue EDARBI as soon as possible. Drugs that act directly on the renin-angiotensin system

can cause injury and death to the developing fetus. See WARNINGS AND PRECAUTIONS in complete Prescribing

Information.

25

TAK-OEC

Monitor for worsening renal function in patients with renal impairment: In patients whose renal function may depend on the activity of the renin‐angiotensin system, treatment with ACE inhibitors and ARBs has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death. Similar results may be anticipated in patients treated with EDARBI. In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported. There has been no long‐term use of EDARBI in these patients but similar results may be expected.

Important Safety Information (cont.)

Please see Takeda representative for complete Prescribing Information. 26

TAK-OEC

Drug Interactions: Monitor renal function periodically in patients receiving EDARBI and NSAIDs who are also elderly, volume‐depleted (including those on diuretics), or who have compromised renal function due to potential reversible deterioration of renal function.

Adverse Reactions: The most common adverse reaction that occurred more frequently with EDARBI than placebo in adults was diarrhea (2% vs. 0.5%).

Important Safety Information (cont.)

Please see Takeda representative for complete Prescribing Information. 27

TAK-OEC

EDARBI Key Points

EDARBI 80 mg was statistically superior to Diovan® 320 mg and Benicar® 40 mg in reducing 24-hour mean ambulatory and clinic systolic blood pressure (SBP) in head-to-head studies

EDARBI 80 mg sustained significant SBP reductions across the 24-hour dosing interval

Treatment with EDARBI was well tolerated, and the most common adverse reaction occurring more frequently with EDARBI than placebo in adults was diarrhea (2% vs. 0.5%)

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File. Trademarks are the property of their respective owners.

1. EDARBI (azilsartan medoxomil). Package Insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011. 2. Data on File. Trademarks are the property of their respective owners. 28


TAK-OEC

EDARBI Key Points (cont.)

Additional reduction in 24-hour mean ambulatory SBP with EDARBI 80 mg when co-administered with:

– CLD 25 mg compared with CLD 25 mg alone

– AML 5 mg compared with AML 5 mg alone

Small reversible increases in serum creatinine are seen in patients receiving 80 mg of EDARBI. The increase may be larger when co-administered with chlorthalidone or hydrochlorothiazide and was more likely in patients who had moderate to severe renal impairment at baseline or >75 years of age



A clinical update_in_hypertension

Health & Medicine

Transcript of A clinical update_in_hypertension